Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus

摘要: The mTOR inhibitor everolimus (EVL) can be used for calcineurin inhibitor-sparing immunosuppression in heart transplantation (HTx). However, comparable data regarding clinical outcomes HTx recipients receiving EVL either with dosage reduction of cyclosporine A (CSA) or tacrolimus (TAC) is scarce. In a retrospective analysis, we compared 5-year 154 maintenance patients CSA (n=106) TAC (n=48). primary endpoint was composite death, graft loss and discontinuation (treatment failure). Secondary endpoints were kidney function, cardiac rejection, cytomegalovirus infection biochemical safety parameters. the group, reached by 59.8% 53.1%, respectively (P=0.716). Five-year mortality 30.4% (CSA group) 23.13% (TAC group), (P=0.371), freedom from 53.3% 59.6% (P=0.566) respective groups. Covariate-adjusted relative risk treatment failure group=1.28 (95% CI: 0.70-2.34; P=0.43) group. course covariate-adjusted estimated glomerular filtration rate similar two groups (P=0.502 P=0.476), whereas rejection lower group (P=0.023). Lipid status blood cell counts between conclusion, indicate that plus reduced not superior to function. CSA, seems reduce rejections.